Protection against SARS-CoV-2 may be short-lived

Since reinfection can occur, the only safe and effective way to achieve herd immunity may be through vaccination

Updated - September 19, 2020 08:09 pm IST

Word of caution:  Care is needed when compiling policies relying on long-term immunity, either through natural infection or vaccinatio, aimed at attaining herd immunity.

Word of caution: Care is needed when compiling policies relying on long-term immunity, either through natural infection or vaccinatio, aimed at attaining herd immunity.

While it is generally known that protective immunity against the four species of common cold coronaviruses does not last for more than year, a study that monitored 10 healthy individuals for more than 35 years revealed that reinfection with the same seasonal coronavirus occurred frequently at 12 months after infection. This observation suggests that the duration of protection against SARS-CoV-2 reinfection, too, may not be for long, and reinfection, which is a common feature of all human coronaviruses, might take place for SARS-CoV-2, too.

The four common cold coronaviruses belong to two different genera and use different receptors found on different host cells that allow the virus to gain entry and infect the cells.

Key question

With over a dozen cases of reinfection with SARS-CoV-2, first reported from Hong Kong and then from the U.S and recently from India and other countries, as confirmed through genetic sequences, the key question centres around the duration of protection following an infection by SARS-CoV-2 virus. Insights gained from the longitudinal study published in Nature Medicine suggest reinfection with the same seasonal coronavirus occurred frequently around one year after previous infection. The short duration of protection against seasonal coronaviruses reinfection might be applicable for SARS-CoV-2 virus too.

Caution needed

“We hypothesise that characteristics shared by these four seasonal coronaviruses, such as the duration of protective immunity, are representative of all human coronaviruses, including SARS-CoV-2,” the authors write. The findings of the study suggest that “caution may be needed” when coming up with policies by relying on long-term immunity either through natural infection or vaccination aimed at attaining herd immunity.

“I would not be at all surprised to see more reinfection cases [from SARS-CoV-2] to be reported in the future,” Prof. Akiko Iwasaki, an immunologist at Yale University, says in an email to The Hindu. “Since reinfection can occur, herd immunity by natural infection is unlikely to eliminate SARS-CoV-2. The only safe and effective way to achieve herd immunity is through vaccination,” Prof. Iwasaki tweeted.

For the study, the researchers used serum samples of adult males who were monitored at regular intervals since the 1980s to investigate how often seasonal coronavirus infections occurred during follow-up. The authors chose 10 healthy individuals from the cohort, and serum samples collected from them every three months before 1989 and every six months afterwards were used for the current study; no samples were collected between 1997 and 2003.

Role of antibodies

The researchers measured the antibodies to the nucleocapsid protein — an abundant coronavirus protein — for each seasonal coronavirus. An increase in antibodies was considered a new infection. While reinfections were seen in a few cases within six and nine months, they were more frequent at 12 months. No intermediate reduction in antibodies between infections were seen in the case of reinfections occurring as early as six months, but they did observe intermediate reductions between infections in the case of reinfections occurring more than six months.

Since antibodies induced by coronavirus infections might have broad coronavirus-recognising characteristics, they studied the complete nucleocapsid protein of SARS-CoV-2 to enable detection of broadly recognising antibodies.

While two adults showed broadly recognising antibodies, and antibodies in one person remained present in the following years, no evidence of induction and maintenance of these antibodies were seen. “These sustained broadly recognising antibodies did not provide broad protection from subsequent infections,” they write.

Strain variation

The researchers were not able to identify strain variation among seasonal coronaviruses that could play a role in susceptibility to reinfection. Since there is only slightly varying circulating SARS-CoV-2 strains, increased susceptibility to reinfection by divergent virus strains of SARS-CoV-2 is most likely not the case, they note.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.